Clinical Trial Update: A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated RO5024048 in combination with ritonavir-boosted danoprevir, with or without ribavirin, in interferon-naïve patients with chronic hepat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Danoprevir (danoprevir)
• RO5024048
• Ribavirin (ribavirin)
• Ritonavir (Ritonavir)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED